The invention is directed toward bioreactor assemblies.
Many cooling and filtration devices rely upon a continuous or semi-continues flow of feed water. When the feed source contains bio-nutrients, biofouling often occurs. As a result, such devices experience a loss in heat exchange efficiency and/or an undesirable pressure drop. Moreover, when biofouling occurs on closely spaced membrane surfaces, the overall efficiency of mass transfer is adversely affected.
Biofouling may be mitigated by introducing oxidants (e.g. bleach), biocides or biostatic agents into the feed water. Feed water may also be pre-treated with a bioreactor to reduce bio-nutrients that would otherwise contribute to biofouling of downstream devices. Examples are described in US2012/0193287; U.S. Pat. No. 7,045,063, EP127243; and H. C. Hemming et al., Desalination, 113 (1997) 215-225; H. Brouwer et al., Desalination, vol. 11, issues 1-3 (2006) 15-17. In each of these examples, feed water is pre-treated with a bioreactor at a location upstream from use. See also: US2012074995, GB1509712, JP2013202548, WO199638387, DE3413551 and DE102012011816.
New techniques for removing bio-nutrients from feed water are desired. In particular, new bioreactor designs are desired, including those suited for removing the most assimilable bio-nutrients in a continuous or semi-continues manner.
In a preferred embodiment, the invention includes a bioreactor assembly for treating a feed fluid (e.g. water) including:
i) a pressure vessel comprising an inner peripheral surface defining an inner chamber having a cross-sectional area, and a first and second port adapted to provide fluid access with the inner chamber,
ii) a plurality of bioreactors located within the inner chamber, wherein each bioreactor includes an outer periphery and flow channels extending along bio-growth surfaces from an inlet region to an outlet region, and
iii) a fluid flow pathway adapted for connection to a source of feed water and extending from the first port of the pressure vessel, along a parallel flow pattern to each bioreactor, into the flow channels of each bioreactor, and out the second port of the pressure vessel.
In a preferred embodiment, the bioreactors are positioned in a serial arrangement within the inner chamber of the pressure vessel. In another embodiment, a plurality of assemblies including multiple pressure vessels with multiple bioreactors may be used.
The bioreactor assembly may serve as a pre-treatment for water used in downstream operations, including heating or cooling (e.g. heat exchangers, humidifiers, cooling towers, etc.) and filtration (e.g. reverse osmosis, nanofiltration, forward osmosis, ultrafiltration, microfiltration, cartridge filters, membrane distillation, membrane degasification, etc.) devices. Absent the reduction in bio-nutrients in the feed water, such downstream operations may experience significant biofouling that can reduce efficiency.
The figures are not to scale and include idealized views to facilitate description. Where to possible, like numerals have been used throughout the figures and written description to designate the same or similar features.
The invention includes a bioreactor assembly useful for treating various aqueous feeds (e.g. brackish water, sea water, waste water, etc.) that include bio-nutrients (e.g. dissolved and suspended biological matter). The bioreactor includes flow channels extending along bio-growth surfaces from an inlet region to an outlet region. Incoming feed fluid enters the inlet region and passes through the flow channels to the outlet region. The bio-growth surfaces (growth media) provide a platform for microorganisms to colonize and consume bio-nutrients in the feed fluid as it passes through the bioreactor. As will be described, several embodiments of bio-growth surfaces are suitable, including flat sheets, particles, etc. The inlet region and outlet region are located adjacent to the growth media to and do not necessarily correspond to the outer-most dimensions of a bioreactor where feed fluid may enter and exit.
In a preferred embodiment, the bioreactor assembly includes at least one, and preferably a plurality of bioreactors located within an inner chamber of a pressure vessel. The pressure vessel includes a first and second port adapted to provide fluid access to an inner chamber. A fluid flow pathway extends from the first port, into the inlet region of the bioreactor and through the flow channels of the bioreactor and out the outlet region of the bioreactor and second port of the pressure vessel. The fluid flow pathway is adapted to connection to a source of feed fluid. An inner peripheral surface of the pressure vessel defines an inner chamber that is preferably cylindrical and the bioreactor preferably includes a cylindrical outer periphery.
While a plurality of bioreactors may be positioned in a parallel or serial arrangement within a common pressure vessel, the fluid flow pathway is preferably follows a parallel flow pattern through bioreactor.
In preferred embodiments, the inner chamber of the pressure vessel extends along an axis (Y′) between opposing ends. At least 15% (and more preferably 20%, 25% or even 30%) of the cross-sectional area (i.e. taken in a perpendicular direction to axis Y′ and at any location along the axis Y′) of the inner chamber, excluding the area of the flow channels (of bioreactors that may be located at the point at which the cross section is measured), is free space accessible to the fluid flow pathway. This arrangement provides adequate fluid flow through the inner chamber to supply each bioreactor with a parallel flow of feed fluid with reduced pressure drop.
As will be described, a variety of bioreactor configurations may be used. For example, the bioreactor may include a central hollow conduit, a porous cylindrical shell and a particulate or filamentous growth media; the growth media provides the bio-growth surfaces and defines flow channels therebetween that fluidly connect the central hollow conduit and the porous cylindrical shell. In an alternative embodiment, the bioreactor may include a flat sheet having two opposing bio-growth surfaces and a feed spacer spirally wound about an axis (Y) to form a cylindrical outer peripheral surface. The flat sheet may be porous or non-porous, and the feed spacer provides flow channels between adjacent bio-growth surfaces that provide a path for fluid to pass through the bioreactor without passing through the flat sheet.
The bioreactor assembly may be used as pre-treatment for water used in a downstream cooling/heating or filtration device—particularly those that are vulnerable to biofouling and otherwise difficult or expensive to clean. Examples of heating and cooling devices include: heat exchangers, humidifiers, and cooling towers. Examples of filtration device include: reverse osmosis, nanofiltration, forward osmosis, ultrafiltration, microfiltration, membrane distillation, membrane degasification units. The bioreactor assembly is conducive to pre-treating a continuous flow of water and removing the most assimilable food from the water to prevent or delay biofouling in the downstream device. A plurality of bioreactor assemblies in parallel within a larger treatment assembly enables the periodic removal and cleaning of individual bioreactor assemblies while still providing a continuous supply of pre-treated water to a downstream device that would otherwise be subject to fouling.
In a preferred embodiment, the downstream device is a reverse osmosis (RO) or nanofiltration (NF) apparatus, collectively referred to as “hyperfiltration”. The hyperfiltration assembly includes: a) a high pressure vessel including a feed port, concentrate port and permeate port, and b) a plurality of serially arranged spiral wound hyperfiltration membrane modules located within the high pressure vessel and each including at least one membrane envelope wound around a permeate tube forming a permeate pathway to the permeate port. With such an arrangement, bio-nutrients present in the feed fluid are consumed by microorganisms present in the bioreactor assembly and are less available to cause biofouling in the downstream hyperfiltration assembly.
The hyperfiltration assembly includes a plurality of spiral wound membrane modules located in a serial arrangement and serial flow pattern within a common (high) pressure vessel. In operation, a source of pressurized feed fluid (e.g. waste water pressurized to 0.1 to 1 MPa) passes along a fluid flow pathway successively through the bioreactor assembly and hyperfiltration assembly. Additional filter unit operations may be included along the fluid flow pathway. For example, a microfiltration device (average pore diameter of from 0.1 to 10 μm) or ultrafiltration device (average pore diameter of 0.001-0.1 μm) e.g. hollow fiber membrane module, or cartridge filter (average pore diameter of from 10 to 50 μm) may be positioned along the fluid flow pathway at a location including between the hyperfiltration assembly and the bioreactor assembly and between a feed fluid source and the bioreactor assembly. Various combinations of one or more bioreactor assemblies may be used with one or more hyperfiltration assemblies. For example, a single bioreactor assembly may supply pre-treated fluid to a plurality of hyperfiltration assemblies, either positioned in a parallel flow configuration with each other, or in a serial configuration wherein either permeate or concentrate from a first (upstream) hyperfiltration assembly is supplied to a downstream hyperfiltration assembly. Similarly, multiple bioreactors arranged in a parallel flow configuration may supply one or more common downstream hyperfiltration assembly.
Spiral wound hyperfiltration membrane modules (“elements”) useful in the present invention include one or more membrane envelops and feed spacer sheets wound around a permeate collection tube. RO membranes used to form envelops are relatively impermeable to virtually all dissolved salts and typically reject more than about 95% of salts having monovalent ions such as sodium chloride. RO membranes also typically reject more than about 95% of inorganic molecules as well as organic molecules with molecular weights greater than approximately 100 Daltons. NF membranes are more permeable than RO membranes and typically reject less than about 95% of salts having monovalent ions while rejecting more than about 50% (and often more than 90%) of salts having divalent ions—depending upon the species of divalent ion. NF membranes also typically reject particles in the nanometer range as well as organic molecules having molecular weights greater than approximately 200 to 500 Daltons.
A representative spiral wound membrane module is generally shown in
During module fabrication, permeate spacer sheets (12) may be attached about the circumference of the permeate collection tube (8) with membrane leaf packets interleaved there between. The back sides (36) of adjacently positioned membrane leaves (10, 10′) are sealed about portions of their periphery (16, 18, 20) to enclose the permeate spacer sheet (12) to form a membrane envelope (4). Suitable techniques for attaching the permeate spacer sheet to the permeate collection tube are described in U.S. Pat. No. 5,538,642. The membrane envelope(s) (4) and feed spacer(s) (6) are wound or “rolled” concentrically about the permeate collection tube (8) to form two opposing scroll faces (30, 32) at opposing ends and the resulting spiral bundle is held in place, such as by tape or other means. The scroll faces of the (30, 32) may then be trimmed and a sealant may optionally be applied at the junction between the scroll face (30, 32) and permeate collection tube (8), as described in U.S. Pat. No. 7,951,295. Long glass fibers may be wound about the partially constructed module and resin (e.g. liquid epoxy) applied and hardened. In an alternative embodiment, tape may be applied upon the circumference of the wound module as described in U.S. Pat. No. 8,142,588. The ends of modules may be fitted with an anti-telescoping device or end cap (not shown) designed to prevent membrane envelopes from shifting under the pressure differential between the inlet and outlet scroll ends of the module. Representative examples are described in: U.S. Pat. No. 5,851,356, U.S. Pat. No. 6,224,767, U.S. Pat. No. 7,063,789, U.S. Pat. No. 7,198,719 and WO2014/120589.
Arrows shown in
While modules are available in a variety of sizes, one common industrial RO module is available with a standard 8 inch (20.3 cm) diameter and 40 inch (101.6 cm) length. For a typical 8 inch diameter module, 26 to 30 individual membrane envelopes are wound around the permeate collection tube (i.e. for permeate collection tubes having an outer diameter of from about 1.5 to 1.9 inches (3.8 cm-4.8 cm)). Less conventional modules may also be used, including those described in U.S. Pat. No. 8,496,825. In a preferred embodiment, at least one spiral wound hyperfiltration modules downstream of the bioreactor assembly uses a feed spacer of less than 20 mil (0.508 mm) or even less than 15 mil (0.381 mm) thickness.
An individual pressure vessel or a group of vessels working together, each equipped with one or more spiral wound membrane modules, can be referred to as a “train” or “pass.” The vessel(s) within the pass may be arranged in one or more stages, wherein each stage contains one or more vessels operating in parallel with respect to a feed fluid. Multiple stages are arranged in series, with the concentrate fluid from an upstream stage being used as feed fluid for the downstream stage, while the permeate from each stage is collected without further reprocessing within the pass. Multi-pass hyperfiltration systems are constructed by interconnecting individual passes along a fluid pathway as described in: U.S. Pat. No. 4,156,645, U.S. Pat. No. 6,187,200, U.S. Pat. No. 7,144,511 and WO2013/130312.
One preferred type of bioreactor has a spiral wound configuration similar to that described above with respect to the membrane modules. However, as no fluid separation occurs in the bioreactor, the bioreactor preferably includes no membrane envelope. As best shown in
In specific regard to the embodiment illustrated in
The bioreactors (52) do not function as spiral wound membrane modules in that their flat sheet does not separate the feed solution into permeate and concentrate streams. Rather, flow channels (68) provide a direct path from the inlet region (61) to the outlet region (63) without to passing through the flat sheet (54) to produce a permeate. For example, in the embodiment of
The feed spacer (58) preferably provides flow channels (68) of between 0.1 mm and 1.5 mm and more preferably between 0.15 mm and 1.0 mm, between adjacent bio-growth surfaces (56, 56′). A channel of less than 0.15 mm is more easily occluded by bio-growth, so that pressure drop through the flow channels requires more frequent cleanings. A channel of greater than 1.0 mm is less efficient at creating bio-growth that is desired to consume bio-nutrients. The spiral wound bioreactor (52) may be made with more than one overlapping flat sheet and spacer, but it is preferred to use at most two flat sheets (54) separated by spacers (58). Most preferably, each bioreactor comprises only a single spiral wound flat sheet (54).
Bio-growth surfaces are defined as those surfaces adjacent the flow channels (68) that connect the inlet region (61) and outlet region (63). In
The feed spacer (58) to be used within a spiral wound bioreactor (52) is not particularly limited and includes the feed spacers described above in connection with spiral wound membrane modules. It is desired that the majority of flat sheet adjacent a spacer is not occluded by contact with the spacer. Preferred structures for spacers include a net-like sheet material having intersection points of greater thickness than the average thickness of strands therebetween. The spacer may be a collection of raised regions of the flat sheet, such as formed by a bossing step, by application of adhesive lines to the flat sheet, or by affixing of appropriately-sized core/shell balls to the surface. Once spirally wound, the feed spacer preferably provides flow channels of from 0.10 mm to 1.5 mm, more preferably 0.15 mm to 1.0 mm, between adjacent bio-growth surfaces of the flat sheet. When provided in a sheet format, proximate feed spacer (58) and flat sheet (54) sections may be selectively bound together, e.g. adhered together along portions of their periphery or intermittent regions on their surfaces. Similarly, adjacent bio-growth surfaces may be affixed at some locations to prevent relative movement therebetween, but still allow feed movement through the flow channel. Such bonding adds strength to the bioreactor, preventing extrusion of the spacer and mitigating telescoping.
The flat sheet (54) of a bioreactor (52) may be impermeable. Alternatively, to aid in cleaning, the opposing bio-growth surfaces (56, 56′) may be in fluid communication with each other through the matrix of a porous flat sheet (54). While not particularly limited, a permeable flat sheet may include a generally impermeable sheet with perforations, a UF or MF membrane, a woven or nonwoven material, fibrous matrix, etc. Examples of suitable materials are described in U.S. Pat. No. 5,563,069. However, unlike the general design described in U.S. Pat. No. 5,563,069, the flat sheet in a spiral wound bioreactor of the present invention includes bio-growth surfaces (56, 56′) on both outer faces which are separated by a feed spacer (58). Also, while the flat sheet (54) may be either permeable or impermeable, the feed spacer (58) provides flow channels (68) between adjacent bio-growth surfaces (56, 56′) that provide a path for fluid to pass through the bioreactor (52), from an inlet region (61) to an outlet region (63), without passing through the flat sheet (54). Preferred materials include polymer sheets having pore sizes greater than 0.1 μm, or greater than 10 μm. The polymer sheet may also include macropores of sizes greater than 10 μm which facilitate disturbing fluid into fouled regions during cleaning. Applicable polymers include but are not limited to polyethylene, polypropylene, polysulfone, polyether sulfone, polyamides, and polyvinylidene fluoride. As the bioreactor of this invention preferably operates at relatively high flow rates, the flat sheet thickness is preferably less than the spacer thickness. Preferably, the flat sheet thickness is less than 1 mm, and more preferably less than 0.5 mm, less than 0.2 mm, or even less than 0.1 mm. The thickness of the flat sheet (54) in bioreactors (52) is preferably less than 25% of the thickness of a membrane envelope (4) in downstream hyperfiltration modules (2).
In embodiments where the subject bioreactor assembly is located upstream from a downstream hyperfiltration assembly, the unrolled length of flat sheet (54) from a bioreactor (52) preferably exceeds the unrolled length of a membrane envelope (4) from a downstream hyperfiltration module (2) by at least a factor of three, and more preferably by at least a factor of ten. (In this context, the unrolled lengths of flat sheet (54) and membrane envelope (4) are measured in the direction perpendicular to a central axis (X or Y, respectively, from
The outer peripheral surface (55) of the spiral wound bioreactor (52) is preferably cylindrical and may be finished in the same manner as described above with respect to spiral wound membrane modules, e.g. tape, fiberglass, etc. The bioreactor may alternatively be encased in a molded, shrink-wrapped, or extruded shell (e.g. PVC or CPVC). Alternatively or additionally, the bioreactor may include anti-telescoping devices which are commonly used in connection with spiral wound membrane modules. In one embodiment, the bioreactor includes an end cap that interlocks with an adjacent spiral wound membrane module (see for example U.S. Pat. No. 6,632,356 and U.S. Pat. No. 8,425,773). In another embodiment, to prevent mixing of the feed that has been treated by the bioreactor with feed that has not been treated, the end cap may provide seals for connecting to collection chambers inside the pressure vessel. In another embodiment, the end cap may provide seals and/or locking features for connecting to adjacent bioreactors.
The bioreactor used within the bioreactor assembly of this invention may take different forms. An alternative to the spiral wound bioreactor of
As shown in
In preferred embodiments, the cross-sectional area of the bioreactor(s) is always at least 5% and more preferably less than 10% of the cross-sectional area of the inner chamber of the pressure vessel (wherein the cross sectional area is measured at any location along the length of the inner chamber). Moreover, at least 5% and more preferably 10% of the total cross sectional area of the inner chamber of the pressure vessel between its opposing ends is free space (not occupied by a bioreactor, spacers or other structure) and as such, is accessible to the fluid flow pathway. Such an arrangement provides the means to distribute flow amongst different serially aligned bioreactors in a vessel.
A plurality of bioreactors may be arranged in a parallel (
In
In preferred embodiments, feed flow into and out of a vessel containing multiple bioreactors may be at least four times more than feed entering a downstream hyperfiltration vessel, even if normalized to the cross sectional area of the two pressure vessels (38), (73). At these unusually high flow rates through a vessel, there can be a large pressure drop in the annular region surrounding the bioreactor and in the central hollow conduit. There is also potential for a large pressure drop through the central hollow conduit. Further, calculations have determined that pressure drops down the vessel at these two locations will not cancel, and large variations in flow through different bioreactors at different positions down the vessel can result. It is preferred that variation in water flow between bioreactors within a pressure vessel be kept within less than a factor of two, preferably less than 1.5.
While a pressure vessel containing a plurality of packed spiral wound bioreactors would maximize the incorporation of bio-growth surfaces (media), a preferred embodiment of the bioreactor assembly includes multiple parallel bioreactors within a pressure vessel and substantial free space along the fluid flow pathway, between the outer periphery of the bioreactors and inner peripheral surface of the inner chamber of the pressure.
In order to provide a robust fluid flow pathway, the bioreactors preferably have a smaller outer diameter than the diameter of the inner chamber of the pressure vessel. In still more preferred embodiments, the inner chamber of the pressure vessel extends along an axis (Y′) between opposing ends. At least 15% (and more preferably 20%, 25% or even 30%) of the cross-sectional area (i.e. taken in a perpendicular direction to axis Y′ and at any location along the axis Y′) of the inner chamber, excluding the area of the flow channels (of bioreactors that may be located at the point at which the cross section is measured), is free space accessible to the fluid flow pathway. This arrangement provides adequate fluid flow through the inner chamber to supply each bioreactor with a parallel flow of feed fluid with reduced pressure drop.
In another embodiment, different from those illustrated in
In the embodiment shown in
A bioreactor assembly (72) may alternate between an operating mode and a cleaning mode. In the operating mode, fluid from the first port (80) passes through parallel bioreactors (52), from inlet scroll face (64) to outlet scroll face (66), exiting the bioreactor assembly at its second port (82). The cleaning flow pathway may be reversed, or combinations of flow directions may be used. The cleaning assembly may include a separate pump (100) and valve assembly (102). The cleaning assembly (96) and related flow path are isolated from the hyperfiltration assemblies (38), and as such, a wider range of cleaning agents may be used without compromising the integrity of the membranes of the hyperfiltration assemblies (38). Representative cleaning agents include acid solutions having a pH of less than 2, basic solutions having a pH greater than 12, solutions including biocides, aqueous solutions at elevated temperature (e.g. greater than 40° C., 60° C. or 80° C.), and oxidants, e.g. aqueous chlorine solutions (e.g. at least 10 ppm, 100 ppm or even 1000 ppm of chlorine). Preferably, the cleaning fluid has an average residence time of less than 10 seconds (1 to 10 seconds) within the bioreactor; more preferably the average residence is less than 5 seconds within the bioreactor.
After cleaning, the bioreactor assembly (72) may be flushed, e.g. with one or more of clean water, feed fluid, or an inoculation solution including microorganisms in a manner similar to that described with respect to the cleaning assembly. The inoculation solution may include liquid previously extracted from the bioreactor assembly (e.g. prior to or during cleaning). A nutrient may also be dosed during at least a part of the operating mode. In a preferred embodiment, the pressure difference across a bioreactor (52) or bioreactor assembly (72) is measured in the operating mode, and switching from the operating mode to the cleaning mode is triggered by the measured pressure difference. Preferably, the pressure difference across the bioreactor assembly (72) is less than 10 psi (more preferably less than 5 psi) after the cleaning mode. In one embodiment, the cleaning mode is commenced after a measured pressure drop of the bioreactor exceeds 10 psi, or more preferably after it exceeds 20 psi.
Many embodiments of the invention have been described and in some instances certain embodiments, selections, ranges, constituents, or other features have been characterized as being “preferred.” Such designations of “preferred” features should in no way be interpreted as an essential or critical aspect of the invention. For instance, it will be appreciated that a spiral wound bioreactor has advantages, but that various alternatives configurations could include hollow fiber, plate and frame, a packed bed of particulates, and a fluidized bed. For other geometries, it is still preferred that the bioreactor be cylindrical, that flow channels (68) extending through the bioreactor have a void volume of at least 65% (more preferably 75% or even 85%) of the volume of the bioreactor, and that the ratio of bio-growth surface area to bioreactor volume for each bioreactor is preferably between 15 cm−1 and 150 cm−1 (more preferably between 20 cm−1 and 100 cm−1).
Additional embodiments and features are described in: U.S. 62/148,365 (PCT/US15/051297); U.S. 62/148,348 (PCT/US15/051297) and U.S. 62/054,408 (PCT/US15/051295). The entire content of each of the aforementioned patents and patent applications are incorporated herein by reference.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2017/020065 | 3/1/2017 | WO | 00 |
Number | Date | Country | |
---|---|---|---|
62315292 | Mar 2016 | US | |
62312186 | Mar 2016 | US |